#BNTC

StockTitan

@stocktitan.net

4 months ago

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update Benitec Biopharma (NASDAQ: BNTC) reported Q1 2026 results on Nov 14, 2025 and provided updates on its BB-301 program for Oculopharyngeal Muscular Dystrophy (OPMD).Clinical: BB-301 achieved positive Phase 1b/2a interim results with a 100% responder rate (6/6) in Cohort 1; the FDA granted Fast Track Designation and the first patient in Cohort 2 was treated in Q4 2025.Financing & cash: Completed an oversubscribed equity offering grossing ~$100 million on Nov 5, 2025; cash and cash equivalents were $94.5 million as of Sep 30, 2025.Financials: Q1 total operating expenses were $9.8M vs $5.8M a year earlier; net loss attributable to shareholders was $9.0M or $(0.22) per share for the quarter.

#BNTC Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

4 months ago

Benitec Biopharma Inc. Announces Proposed Public Offering Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and

#BNTC Benitec Biopharma Inc. Announces Proposed Public Offering

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

4 months ago

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designation from both FDA and EMA All six patients enrolled into

#BNTC Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

www.stocktitan.net/news/BNTC/benitec-biopha...

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NASDAQ: #BNTC ) Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

StockTitan

@stocktitan.net

4 months ago

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on

#BNTC Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

5 months ago

Clinical Progress: Benitec's BB-301 OPMD Gene Therapy Clears Safety Review, Phase 1b/2a Cohort 2 to Begin Biotech reports $41.8M FY2025 loss with $97.7M cash runway. BB-301 gene therapy for OPMD receives DSMB approval for Cohort 2 enrollment. Interim results expected Q4 2025.

#BNTC Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/BNTC/benitec-biopha...

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Small-cap stocks in new downtrend with AROON Oscillator, Mon Jul 28th - #AERT #BNTC #CASS #DMRC #EM #FMBH #IMAB #MPB #NRIM #RGP #XYF #UMH #SITC #OOMA #IFN #GEL #FVRR #CHPT #BFS #AGM #SEGG #WALD #ZJK - More: crystalequityresearch.com/ieading-indi... - #smallcap

StockTitan

@stocktitan.net

8 months ago

Benitec Biopharma Provides Operational Updates Benitec Biopharma (NASDAQ: BNTC) has announced significant progress in its Phase 1b/2a Clinical Treatment Study for BB-301, its gene therapy treatment. The company successfully completed treatment of the sixth and final subject in Cohort 1 with a low dose of BB-301 in April 2025.The Independent Data Safety Monitoring Board (DSMB) has completed its review of all six subjects in Cohort 1 and recommended continuation of subject enrollment. Following this positive recommendation, enrollment for Cohort 2 is expected to begin in Q4 2025. The company reports encouraging results regarding BB-301's safety profile, particularly noting the benefits of their local direct intramuscular delivery method.

#BNTC Benitec Biopharma Provides Operational Updates

www.stocktitan.net/news/BNTC/benitec-biopha...

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks with strong volume declines, Wed Jun 18th - #SNTI #INV #IMDX #EKSO #DXLG #BNTC #ACB #DDD #BPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks with strong volume declines, Tue Jun 17th - #YQ #SEDG #RUN #IMRX #FGEN #BNTC #ALDF #VNCE #RDW #LTM #FVR #CTRI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

Benitec Biopharma Releases Third Quarter 2025 Financial Results Benitec Biopharma (NASDAQ: BNTC) reported its Q3 2025 financial results. The company's net loss widened to $9.4 million ($0.24 per share) compared to $4.3 million ($0.23 per share) in Q3 2024. Total expenses increased to $10.2 million from $4.1 million year-over-year, with R&D expenses rising to $6.0 million and G&A expenses reaching $4.2 million. The company maintains a strong cash position of $103.6 million. On the clinical front, Benitec completed treatment of the sixth and final Subject in Cohort 1 with the low dose of BB-301, their gene therapy treatment for OPMD (Oculopharyngeal Muscular Dystrophy). The company plans to enroll additional subjects at a higher dose later this year, with clinical updates for Cohort 1 expected in Q4 2025.

#BNTC Benitec Biopharma Releases Third Quarter 2025 Financial Results

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

11 months ago

$30M Capital Raise: Benitec Biopharma Lands Major Strategic Investment from Suvretta Capital Strategic $30M stock offering strengthens Benitec's pipeline development capabilities. Suvretta Capital leads investment at $13/share. Full financing details inside.

#BNTC Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

1 year ago

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update Benitec Biopharma (NASDAQ: BNTC) has released its Q2 2025 financial results and provided updates on its BB-301 Phase 1b/2a clinical trial for Oculopharyngeal Muscular Dystrophy (OPMD). The fifth subject was safely treated in February 2025, with interim results showing durable, clinically meaningful improvements in swallowing function for the first subjects treated.Financial highlights for Q2 2025 include:Revenue: $0.0 millionTotal expenses: $8.6 million (up from $6.9 million in Q2 2024)Net loss: $7.4 million, or ($0.33) per shareCash position: $78.3 million as of December 31, 2024The company plans to begin treating a second cohort with a higher dose of BB-301 later in the year. An interim clinical study update will be presented at the 2025 Muscular Dystrophy Association Conference on March 19, 2025.

#BNTC Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

1 year ago

#BNTC Benitec Biopharma to Participate in Upcoming Investor Conferences in December

www.stocktitan.net/news/BNTC/benitec-biopha...

StockTitan

@stocktitan.net

1 year ago

#BNTC Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/BNTC/benitec-biopha...

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #BNTC ) Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #BNTC ) Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

#StockMarket #News